Devonian Health Group is a Canadian publicly-traded (TSXv:GSD; OTCQB: DVHGF) late-stage botanical pharmaceutical corporation that focuses on addressing global unmet medical needs. Their core strategy involves developing prescription botanical drugs derived from plant materials, algae, macroscopic fungi, and combinations thereof. This approach is supported by FDA regulatory guidelines, which provide a more efficient drug development pathway for prescription botanical drug products.

Devonian's botanical drugs offer numerous advantages, including faster and less costly drug development from pre-clinical to proof-of-concept studies (Phase 2), superior risk management, clear indications for specific medical conditions, and accessibility for medication reimbursement plans. Additionally, these drugs have potential marketing exclusivity for up to five years, even without patent protection, making them 'copy-cat' proof. Operating from a state-of-the-art extraction facility in Canada spanning 1,625 square meters, Devonian ensures pharmaceutical-grade production through custom-designed equipment and compliance with Cleanroom Standards.

This scalable extraction platform supports their commercial operations and revenue generation. In 2018, Devonian expanded its capabilities by acquiring Altius Healthcare Inc., a specialty pharmaceutical company focused on acquiring and distributing innovative medicines and healthcare products within Canada. With a commitment to innovation and providing solutions to unmet medical needs, Devonian Health Group continues to advance botanical pharmaceuticals for improved healthcare outcomes